This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2021 Oct 12;12(21):2231.

doi: 10.18632/oncotarget.28012.

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

Joshua E Allen¹, C Leah B Kline², Varun V Prabhu¹, Jessica Wagner², Jo Ishizawa³, Neel Madhukar⁴, Avital Lev², Marie Baumeister², Lanlan Zhou², Amriti Lulla², Martin Stogniew¹, Lee Schalop¹, Cyril Benes^{5

6}, Howard L Kaufman⁷, Richard S Pottorf⁸, B Rao Nallaganchu⁸, Gary L Olson⁸, Fahd Al-Mulla⁹, Madeleine Duvic³, Gen Sheng Wu¹⁰, David T Dicker², Mala K Talekar¹¹, Bora Lim³, Olivier Elemento⁴, Wolfgang Oster¹, Joseph Bertino⁷, Keith Flaherty^{5

6}, Michael L Wang³, Gautam Borthakur³, Michael Andreeff³, Mark Stein⁷, Wafik S El-Deiry²

Affiliations

Affiliations

¹ Oncoceutics, Inc., Philadelphia, PA, USA.
² Fox Chase Cancer Center, Philadelphia, PA, USA.
³ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Weill Cornell Medicine, New York, NY, USA.
⁵ Massachusetts General Hospital, Boston, MA, USA.
⁶ Harvard Medical School, Boston, MA, USA.
⁷ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
⁸ Provid Pharmaceuticals, Monmouth Junction, NJ, USA.
⁹ Kuwait University Medical School, Kuwait.
¹⁰ Karmanos Cancer Institute, Detroit, MI, USA.
¹¹ The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

PMID: 34676056
PMCID: PMC8522842
DOI: 10.18632/oncotarget.28012

Published Erratum

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

Joshua E Allen et al. Oncotarget. 2021.

. 2021 Oct 12;12(21):2231.

doi: 10.18632/oncotarget.28012.

Authors

Joshua E Allen¹, C Leah B Kline², Varun V Prabhu¹, Jessica Wagner², Jo Ishizawa³, Neel Madhukar⁴, Avital Lev², Marie Baumeister², Lanlan Zhou², Amriti Lulla², Martin Stogniew¹, Lee Schalop¹, Cyril Benes^{5

6}, Howard L Kaufman⁷, Richard S Pottorf⁸, B Rao Nallaganchu⁸, Gary L Olson⁸, Fahd Al-Mulla⁹, Madeleine Duvic³, Gen Sheng Wu¹⁰, David T Dicker², Mala K Talekar¹¹, Bora Lim³, Olivier Elemento⁴, Wolfgang Oster¹, Joseph Bertino⁷, Keith Flaherty^{5

6}, Michael L Wang³, Gautam Borthakur³, Michael Andreeff³, Mark Stein⁷, Wafik S El-Deiry²

Affiliations

¹ Oncoceutics, Inc., Philadelphia, PA, USA.
² Fox Chase Cancer Center, Philadelphia, PA, USA.
³ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Weill Cornell Medicine, New York, NY, USA.
⁵ Massachusetts General Hospital, Boston, MA, USA.
⁶ Harvard Medical School, Boston, MA, USA.
⁷ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
⁸ Provid Pharmaceuticals, Monmouth Junction, NJ, USA.
⁹ Kuwait University Medical School, Kuwait.
¹⁰ Karmanos Cancer Institute, Detroit, MI, USA.
¹¹ The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

PMID: 34676056
PMCID: PMC8522842
DOI: 10.18632/oncotarget.28012

Abstract

[This corrects the article DOI: 10.18632/oncotarget.11814.].

Copyright: © 2021 Allen et al.

PubMed Disclaimer

Erratum for

Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Allen JE, et al. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Oncotarget. 2016. PMID: 27602582 Free PMC article. Review.

Publication types

Actions

LinkOut - more resources

Full Text Sources